Marika Alborghetti

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

The Antidepressant Vortioxetine Potently Inhibits Cell Growth in Cultured Human Glioblastoma Cells Expressing 5-HT1B Serotonin Receptors.

The Antidepressant Vortioxetine Potently Inhibits Cell Growth in Cultured Human Glioblastoma Cells Expressing 5-HT1B Serotonin Receptors.

Journal: Cells

Published: April 15, 2026

An update on the pharmacokinetic and pharmacodynamic interactions between antidepressants and antiseizure medications.

An update on the pharmacokinetic and pharmacodynamic interactions between antidepressants and antiseizure medications.

Journal: Expert opinion on drug metabolism & toxicology

Published: March 24, 2026

Overexpression of the Ubiquitin Ligase RNF182 Is Associated with High-Grade Gliomas.

Overexpression of the Ubiquitin Ligase RNF182 Is Associated with High-Grade Gliomas.

Journal: Cancers

Published: March 19, 2026

Perineuronal nets in the insular cortex shape salience-related behaviour in diabetes.

Perineuronal nets in the insular cortex shape salience-related behaviour in diabetes.

Journal: Neurobiology of disease

Published: January 09, 2026

Treatment stability comparison among different ADD-ON therapies in fluctuating Parkinson's disease patients: the role of clinical and demographic factors.

Treatment stability comparison among different ADD-ON therapies in fluctuating Parkinson's disease patients: the role of clinical and demographic factors.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: December 15, 2025

Metabotropic glutamate receptors in the testis: An integrative bioinformatic review of neuroendocrine, reproductive, and Neuropsychopharmacological aspects.

Metabotropic glutamate receptors in the testis: An integrative bioinformatic review of neuroendocrine, reproductive, and Neuropsychopharmacological aspects.

Journal: Progress in neuro-psychopharmacology & biological psychiatry

Published: December 07, 2025

Comparative effect of vortioxetine and sertraline on clinical and inflammatory profile in Parkinson's disease with comorbid depression.

Comparative effect of vortioxetine and sertraline on clinical and inflammatory profile in Parkinson's disease with comorbid depression.

Journal: Frontiers in neuroscience

Published: December 05, 2025

Foslevodopa/Foscarbidopa Overnight Administration Improves Nocturia in Patients with Parkinson's Disease: Evidence from a Real-World Study.

Foslevodopa/Foscarbidopa Overnight Administration Improves Nocturia in Patients with Parkinson's Disease: Evidence from a Real-World Study.

Journal: Movement disorders clinical practice

Published: November 05, 2025

Exploring drug interactions between newer antidepressants and medications used to treat neurological disorders.

Exploring drug interactions between newer antidepressants and medications used to treat neurological disorders.

Journal: Expert opinion on drug metabolism & toxicology

Published: September 25, 2025

Effects of Drugs for the Treatment of Multiple Sclerosis in Severe Acute Respiratory Syndrome Coronavirus 2 Infection on the Expression of Angiotensin-converting Enzyme 2 in vitro.

Effects of Drugs for the Treatment of Multiple Sclerosis in Severe Acute Respiratory Syndrome Coronavirus 2 Infection on the Expression of Angiotensin-converting Enzyme 2 in vitro.

Journal: Current neuropharmacology

Published: September 20, 2025

Telerehabilitation for the treatment of nocturnal hypokinesia in people with Parkinson's disease: a pilot study.

Telerehabilitation for the treatment of nocturnal hypokinesia in people with Parkinson's disease: a pilot study.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: September 08, 2025

Targeting metabotropic glutamate receptors for symptomatic and disease-modifying treatment in Parkinson's disease.

Targeting metabotropic glutamate receptors for symptomatic and disease-modifying treatment in Parkinson's disease.

Journal: NPJ Parkinson's disease

Published: June 27, 2025

Showing 1-12 of 43

Last Updated: 09/26/2026